Skip to main content
  • Saved

made a Post

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol - PubMed

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33556413/

1 Department of Endocrinology and Metabolism, Dokkyo Medical University, Japan. Electronic address: jojima@dokkyomed.ac.jp. 2 Department of Endocrinology and Metabolism, Dokkyo Medical University, Japan. 3 Department of Infection Control and Clinical Laboratory Medicine, Dokkyo Medical University, Tochigi 321-0293, Japan. 1 Department of Endocrinology and Metabolism, Dokkyo Medical University, Japan. Electronic address: jojima@dokkyomed.ac.jp.